FDA Opens Floor For Debate Of Off-Label Claims, First Amendment Issues
This article was originally published in The Gray Sheet
Executive Summary
FDA's request for comments on First Amendment issues creates a forum for stakeholders to submit comments on FDA's policy regarding off-label claims
You may also be interested in...
FDA Approps Amendment Targets Chief Counsel Troy
FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts
FDA Approps Amendment Targets Chief Counsel Troy
FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts
FDA First Amendment Plan: Series Of Guidances Rather Than Omnibus Rule
FDA's policy on regulating commercial speech will be addressed through a series of guidances and rules related to specific areas of interest